Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H18N6O |
| Molecular Weight | 382.4179 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=NN=C(N1C2=CC=CC3=NON=C23)C4=CC=C(N=C4)C5=CC=CC=C5
InChI
InChIKey=FQGLDGKVKDPVLO-UHFFFAOYSA-N
InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3
| Molecular Formula | C22H18N6O |
| Molecular Weight | 382.4179 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:29 UTC 2023
by
admin
on
Sat Dec 16 11:40:29 UTC 2023
|
| Record UNII |
6627LI8F9K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9800113
Created by
admin on Sat Dec 16 11:40:29 UTC 2023 , Edited by admin on Sat Dec 16 11:40:29 UTC 2023
|
PRIMARY | |||
|
6627LI8F9K
Created by
admin on Sat Dec 16 11:40:29 UTC 2023 , Edited by admin on Sat Dec 16 11:40:29 UTC 2023
|
PRIMARY | |||
|
374886-51-8
Created by
admin on Sat Dec 16 11:40:29 UTC 2023 , Edited by admin on Sat Dec 16 11:40:29 UTC 2023
|
PRIMARY | |||
|
ASP-2535
Created by
admin on Sat Dec 16 11:40:29 UTC 2023 , Edited by admin on Sat Dec 16 11:40:29 UTC 2023
|
PRIMARY | ASP 2535: Cat. No. 5308Biological Activity: Potent and selective GlyT1 inhibitor (IC50 = 92 nM). Exhibits 50-fold selectivity over GlyT2. Attenuates MK 801-induced working memory deficits and PCP-induced visual learning deficits in mice. Orally available and brain penetrant. | ||
|
300000042369
Created by
admin on Sat Dec 16 11:40:29 UTC 2023 , Edited by admin on Sat Dec 16 11:40:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Astellas Pharma; Class: Antidementia, Antipsychotic; Highest Development Phases: Discontinued for Alzheimer's disease, Schizophrenia; Most Recent Events: 29 May 2009 Discontinued - Phase-I for Schizophrenia in Japan (PO), 29 May 2009 Discontinued - Phase-I for Alzheimer's disease in Japan (PO), 29 Aug 2008 Phase-I clinical trials in Schizophrenia in Japan (PO)
|
